Iteos Home

Press Releases

Home / Investors / iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

Press Release Details

iTeos Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

August 8, 2017
PDF Version

Gosselies, Belgium – August 8, 2017 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that Michel Detheux, iTeos’ Chief Executive Officer, will present a company overview at the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017 at 12:45 a.m. ET in New York, NY.

 

About iTeos Therapeutics SA

iTeos is focused on expanding the benefits of immunotherapy for cancer patients by developing a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic (“cold”) tumors. It has licensed its IDO1 program, currently in Phase 1 development, to Pfizer. iTeos’ competitive edge is in the combination of expertise in drug discovery, translational tumor immunology and early clinical trial design. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. Based in Gosselies, Belgium, iTeos is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information, please visit www.iteostherapeutics.com.

 

For further information, please contact:

Michel Detheux, CEO

iTeos Therapeutics

+32 71 919 933

michel.detheux@iteostherapeutics.com

 

Sarah McCabe

Stern Investor Relations, Inc.

+ 1 212 362-1200

sarah@sternir.com

 

Amber Fennell, Mathew Neal, Hendrik Thys

Consilium Strategic Communications

+44 203 709 5700

iteos@consilium-comms.com

For investors

Discover more about iTeos Therapeutics, our science, and our high potential for investment.

scientist picking up a petri dish

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.